PD-L1 — Drug Target

All drugs that target PD-L1 — marketed and clinical-stage. Includes 9 drug classes acting on this target.

Drug classes

PD-L1 inhibitor · Monoclonal antibody · Programmed Death Ligand-1 Blocker [EPC] · Immunotherapy · PD-L1 inhibitor + chemotherapy combination · PD-1/PD-L1 inhibitor · PD-L1 inhibitor plus chemotherapy combination · PD-L1 inhibitor (in combination with chemotherapy) · PD-1 inhibitor

Marketed (8)

• Atezolizumab Injection [Tecentriq] · Nykode Therapeutics ASA · PD-L1 inhibitor · Oncology
  Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on T-cell-mediated anti-tumor immunity.
• AB · GlaxoSmithKline · PD-L1 inhibitor · Oncology
  AB is a monoclonal antibody that binds to and inhibits a specific molecular target to modulate immune or disease-related pathways.
• Avelumab (MSB0010718C) · Pfizer · Monoclonal antibody · Oncology
• AVELUMAB · Programmed Death Ligand-1 Blocker [EPC]
  Avelumab binds to PD-L1, blocking its interaction with PD-1 and B7.1 receptors, restoring immune responses against tumors.
• Pf-06835375 · Pfizer · Immunotherapy · Oncology
• Avelumab first-line maintenance · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · PD-L1 inhibitor · Oncology
  Avelumab is a human monoclonal antibody that blocks PD-L1, releasing immune cells from tumor-induced suppression to attack cancer cells.
• DURVALUMAB · Programmed Death Ligand-1 Blocker [EPC]
  Durvalumab binds to PD-L1, blocking its interaction with PD-1 and CD80, enhancing T-cell activation and reducing tumor size.
• Adebrelimab combined with SOX regimen · Yang Jianjun, PhD · PD-L1 inhibitor · Oncology
  Adebrelimab is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1/PD-L2, restoring anti-tumor immune responses, combined with SOX chemotherapy (S-1 and oxaliplatin) for enhanced cytotoxic and immunological effects.

Phase 3 pipeline (71)

• BCD-281 · Biocad · PD-L1 inhibitor · Oncology
  BCD-281 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
• HLX10 · Shanghai Henlius Biotech · PD-L1 inhibitor · Oncology
  HLX10 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
• GC1107 · Green Cross Corporation · PD-L1 inhibitor · Oncology
  GC1107 is a monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from inhibiting T cell activation.
• HBM9161 Injection (680mg) · Harbour BioMed (Guangzhou) Co. Ltd. · PD-L1 inhibitor · Oncology
  HBM9161 is a monoclonal antibody that blocks the interaction between PD-L1 and its receptors to enhance anti-tumor immune responses.
• BCD-217 · Biocad · PD-L1 inhibitor · Oncology
  BCD-217 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
• CT-P42 · Celltrion · PD-L1 inhibitor · Oncology
  CT-P42 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses.
• INS068 injection · Jiangsu HengRui Medicine Co., Ltd. · PD-L1 inhibitor · Oncology
  INS068 is an anti-PD-L1 monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1/B7.1 on immune cells, thereby restoring anti-tumor immune responses.
• SHR-1209 · Jiangsu HengRui Medicine Co., Ltd. · PD-L1 inhibitor · Oncology
  SHR-1209 is a humanized monoclonal antibody that blocks the interaction between PD-L1 and its receptors (PD-1 and B7-1) to enhance anti-tumor immune responses.
• 9MW0311 · Mabwell (Shanghai) Bioscience Co., Ltd. · PD-L1 inhibitor · Oncology
  9MW0311 is a monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1.
• MEDI4736 (Durvalumab) · Royal Marsden NHS Foundation Trust · PD-L1 inhibitor · Oncology
  Durvalumab is a monoclonal antibody that blocks PD-L1, preventing tumor cells from suppressing the immune system and allowing T cells to attack cancer.
• Atezolizumab(Tecentriq) · Samsung Medical Center · PD-L1 inhibitor · Oncology
  Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on the immune system to attack cancer.
• Durvalumab (Regimen 1) · AstraZeneca · PD-L1 inhibitor · Oncology
  Durvalumab is a monoclonal antibody that blocks PD-L1, preventing tumor cells from evading immune attack and allowing T cells to recognize and kill cancer cells.
• Hemay022+AI · Tianjin Hemay Pharmaceutical Co., Ltd · PD-L1 inhibitor · Oncology
  Hemay022+AI is an anti-PD-L1 monoclonal antibody combined with an AI-optimized therapeutic approach to enhance immune checkpoint inhibition and anti-tumor immunity.
• BCD-148 · Biocad · PD-L1 inhibitor · Oncology
  BCD-148 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
• Avelumab Weekly · EMD Serono Research & Development Institute, Inc. · PD-L1 inhibitor · Oncology
  Avelumab is a human monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and B7.1 receptors to reinvigorate anti-tumor immune responses.
• Adjuvant durvalumab · ETOP IBCSG Partners Foundation · PD-L1 inhibitor · Oncology
  Durvalumab is a PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1/PD-L2 on immune cells, thereby restoring anti-tumor immune responses.
• KN035 plus Gemcitabine & oxaliplatin · 3D Medicines (Sichuan) Co., Ltd. · PD-L1 inhibitor · Oncology
  KN035 is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1/PD-L2, restoring anti-tumor immune responses, combined with gemcitabine and oxaliplatin chemotherapy.
• MHB088C for Injection · Qilu Pharmaceutical Co., Ltd. · PD-L1 inhibitor · Oncology
  MHB088C is a humanized monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1.
• BCD-132 · Biocad · PD-L1 inhibitor · Oncology
  BCD-132 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
• CS1001+ Fluorouracil+Cisplatin · CStone Pharmaceuticals · PD-L1 inhibitor + chemotherapy combination · Oncology
  CS1001 is a PD-L1 inhibitor that blocks immune checkpoint signaling, combined with fluorouracil and cisplatin chemotherapy to enhance anti-tumor immunity and direct cytotoxic effects.
• SHR-1501 for Injection · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · PD-L1 inhibitor · Oncology
  SHR-1501 is a recombinant human anti-PD-L1 monoclonal antibody that blocks the interaction between PD-L1 and PD-1/B7-1, thereby releasing immune checkpoint inhibition and enhancing anti-tumor T-cell responses.
• BCD-100 · Biocad · PD-L1 inhibitor · Oncology
  BCD-100 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
• atezolizumab or durvalumab · Anhui Shi, MD · PD-1/PD-L1 inhibitor · Oncology
  Atezolizumab and durvalumab are monoclonal antibodies that block the PD-L1 protein, preventing cancer cells from evading the immune system.
• MEDI4736 · MedImmune LLC · PD-L1 inhibitor · Oncology
  MEDI4736 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 receptors to enhance anti-tumor immune responses.
• Durvalumab (Regimen 2) · AstraZeneca · PD-L1 inhibitor · Oncology
  Durvalumab is a PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1/PD-L2 on immune cells, thereby restoring anti-tumor immune responses.
• BCD-085 Q4W · Biocad · PD-L1 inhibitor · Oncology
  BCD-085 is a monoclonal antibody that blocks the PD-L1 checkpoint, enabling the immune system to recognize and attack cancer cells.
• TQB2825 Injection · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · PD-L1 inhibitor · Oncology
  TQB2825 is a humanized monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses.
• HLX17 · Shanghai Henlius Biotech · PD-L1 inhibitor · Oncology
  HLX17 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
• HLX14 · Shanghai Henlius Biotech · PD-L1 inhibitor · Oncology
  HLX14 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses.
• HLX22 · Shanghai Henlius Biotech · PD-L1 inhibitor · Oncology
  HLX22 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
• Adebrelimab (PD-L1 inhibitor) · Sun Yat-sen University · PD-L1 inhibitor · Oncology
  Adebrelimab blocks the PD-L1 checkpoint protein on tumor cells, preventing it from suppressing anti-tumor immune responses and allowing T cells to attack cancer.
• Adebrelimab injection · Shanghai Hengrui Pharmaceutical Co., Ltd. · PD-L1 inhibitor · Oncology
  Adebrelimab is a monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from binding to PD-1 and B7.1 receptors on immune cells.
• HLX13 · Shanghai Henlius Biotech · PD-L1 inhibitor · Oncology
  HLX13 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.
• CS1001 monoclonal antibody · CStone Pharmaceuticals · PD-L1 inhibitor · Oncology
  CS1001 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 receptors to enhance anti-tumor immune responses.
• KL-A167 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · PD-L1 inhibitor · Oncology
  KL-A167 is a humanized monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1.
• RTXM83 · mAbxience Research S.L. · PD-1/PD-L1 inhibitor · Oncology
  RTXM83 is a monoclonal antibody targeting PD-L1.
• JS107 for Injection · Shanghai Junshi Bioscience Co., Ltd. · PD-L1 inhibitor · Oncology
  JS107 is a monoclonal antibody that targets and blocks PD-L1, enhancing anti-tumor immune responses by releasing the brakes on T-cell activation.
• A166 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · PD-L1 inhibitor · Oncology
  A166 is an anti-PD-L1 monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1/B7.1 on immune cells, thereby restoring anti-tumor immune responses.
• Atezolizumab and Recombinant Human Hyaluronidase · National Cancer Institute (NCI) · PD-L1 inhibitor · Oncology
  Atezolizumab is a PD-L1 inhibitor that blocks immune checkpoint signaling, combined with recombinant human hyaluronidase to enhance subcutaneous delivery and bioavailability.
• Atezolizumab Injection · Federation Francophone de Cancerologie Digestive · PD-L1 inhibitor · Oncology
  Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on T-cell-mediated anti-tumor immunity.

Phase 2 pipeline (10)

• EMD 72000 · EMD Serono · PD-1/PD-L1 inhibitor · Oncology
  EMD 72000 is a monoclonal antibody targeting PD-L1.
• ASC22 · Ascletis Pharmaceuticals Co., Ltd. · PD-L1 inhibitor · Oncology
  ASC22 is a humanized monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from binding to PD-1 and B7.1 on immune cells.
• MEDI3506 · AstraZeneca · PD-1/PD-L1 inhibitor · Oncology
  MEDI3506 is a monoclonal antibody targeting PD-L1.
• Biological: AZD3152 · AstraZeneca · PD-1/PD-L1 inhibitor · Oncology
  AZD3152 is a monoclonal antibody targeting PD-L1.
• Concurrent chemotherapy and KN026 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd · PD-1/PD-L1 inhibitor · Oncology
  KN026 is a monoclonal antibody targeting PD-L1.
• Anti-PD-L1 Monoclonal Antibody · City of Hope Medical Center · PD-1 inhibitor · Oncology
  Anti-PD-L1 Monoclonal Antibody works by blocking the PD-L1 protein, allowing the immune system to attack cancer cells.
• Anti-PD-L1 antibody atezolizumab · Gustave Roussy, Cancer Campus, Grand Paris · PD-L1 inhibitor · Oncology
  Atezolizumab blocks the PD-L1 checkpoint protein on tumor cells, preventing it from suppressing anti-tumor immune responses and allowing T cells to attack cancer.
• Atezolizumab, Etoposide, Carboplatin, Tarlatamab · Se-Hoon Lee · PD-1/PD-L1 inhibitor · Oncology
  PD-L1 inhibitor
• IBI343,sintilimab,oxaliplatin,S-1 · Innovent Biologics (Suzhou) Co. Ltd. · PD-1/PD-L1 inhibitor · Oncology
  Programmed death-ligand 1 inhibitor
• KN060 Low · Suzhou Alphamab Co., Ltd. · PD-1/PD-L1 inhibitor · Oncology
  KN060 Low is a monoclonal antibody targeting PD-L1.